Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial
Mené sur 180 patients atteints d'un cancer colorectal présentant des microsatellites stables, de stade métastatique et réfractaire (âge médian : 65 ans ; durée médiane de suivi : 15,2 mois), cet essai randomisé évalue l'efficacité, du point de vue de la survie globale et en fonction de la présence de métastases hépatiques, des "meilleurs soins de support" par rapport à un traitement combinant durvalumab et trémélimumab
Résumé en anglais
Importance : Immune checkpoint inhibitors (ICIs) have limited activity in microsatellite-stable (MSS) or mismatch repair–proficient (pMMR) colorectal cancer. Recent findings suggest the efficacy of ICIs may be modulated by the presence of liver metastases (LM).
Objective : To investigate the association between the presence of LM and ICI activity in advanced MSS colorectal cancer.
Design, Setting, and Participants : In this secondary analysis of the Canadian Cancer Trials Group CO26 (CCTG CO.26) randomized clinical trial, patients with treatment-refractory colorectal cancer were randomized in a 2:1 fashion to durvalumab plus tremelimumab or best supportive care alone between August 10, 2016, and June 15, 2017. The primary end point was overall survival (OS) with 80% power and 2-sided
